Efficacy and safety of faricimab for neovascular age-related macular degeneration: a systematic review and network meta-analysis
Objective To evaluate the efficacy and safety of faricimab compared with other anti-vascular endothelial growth factor (anti-VEGF) agents in treating neovascular age-related macular degeneration (nAMD) patients.Methods and analysis A systematic review (SR) was conducted up to January 2023. Network m...
| Egile Nagusiak: | , , , , , , , |
|---|---|
| Formatua: | Artikulua |
| Hizkuntza: | English |
| Argitaratua: |
BMJ Publishing Group
2024-05-01
|
| Saila: | BMJ Open Ophthalmology |
| Sarrera elektronikoa: | https://bmjophth.bmj.com/content/9/1/e001702.full |